Shield Therapeutics plc (LON:STX – Get Free Report) shares rose 5% during mid-day trading on Tuesday . The stock traded as high as GBX 3.39 ($0.04) and last traded at GBX 3.39 ($0.04). Approximately 59,716 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 2,889,450 shares. The stock had previously closed at GBX 3.23 ($0.04).
Shield Therapeutics Stock Performance
The firm has a market cap of £35.51 million, a PE ratio of -0.93 and a beta of 1.42. The company has a 50 day simple moving average of GBX 2.90 and a 200-day simple moving average of GBX 3.43. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16.
Insiders Place Their Bets
In other news, insider Anders Lundstrom bought 575,000 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of GBX 4 ($0.05) per share, with a total value of £23,000 ($29,025.74). 62.16% of the stock is owned by insiders.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Featured Stories
- Five stocks we like better than Shield Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Finding Hidden Gems: Unconventional Penny Stock Investing
- About the Markup Calculator
- Price Targets on NVIDIA Rise in Front of Earnings
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
